The global parenteral nutrition market size is expected to reach USD 8.26 billion by 2026, according to this report, progressing at a CAGR of 5.8% during the forecast period. Increasing rate of natality and surging geriatric population is fueling the market growth.

As of 2014, the natality rate reported by the National Center for Health Statistics (NCHS) is 12.5 births per 1,000 populations in U.S. Furthermore, the percentage of lower weight infants was 8%, thereby boosting the demand for parenteral nutrition products in the country.

The realized natality is rising over the last decade and is anticipated to sustain growth over the forecast period. However, in 2011, a dip was witnessed in U.S. owing to alteration in fertility rate of the local female population. However, in the same year, hike in the number of births for foreign based immigrant citizens was also observed leading to an overall rise in birth rate.

Moreover, a large number of premature babies suffer from low weight as well as undeveloped immunity thus putting them at risk. Parenteral nutrition reduces the risk of infection and underdevelopment, thereby promoting its application.

As per the National Center for Healthcare Statistics, the premature birth rate of the U.S. is about 9.6% as of 2016, and the national authorities are working to reduce it to 8.1%.

In very low birth weight (VLBW) newborns, demand for parenteral nutrition is higher owing to low prospect of enteral nutrition. Hence, use of parenteral nutrition in premature infants results in improved intrauterine nutrient deposition, faster neurological development, and minimized risk of complications thus improving their chances for survival.

Further key findings from the study suggest:

  • Single dose amino acid solution segment dominated the market in 2018 owing to increasing use of amino acid solutions that possess fewer side effects thus enhancing patient benefits.
  • North America led the market in terms of revenue and accounted for 41.73% of the overall share in 2018. Presence of high research expenditure by private entities and government agencies in the healthcare sector and collaborations among medical device industry, regulatory authorities, and universities are responsible for the market growth.
  • Some of the companies present in the parenteral nutrition market are B. Braun Melsungen AG; Baxter International, Inc.; Fresenius Kabi AG; Hospira, Inc.; Actavis, Inc.; Grifols International S.A.; Otsuka Pharmaceutical Factory, Inc.; and Sichuan Kelun Pharmaceutical Co. Ltd.

Key Topics Covered

Chapter 1 Methodology and Scope

1.1 Market Segmentation & Scope

1.2 Research Methodology

1.3 Information Procurement

1.4 Information or Data Analysis

1.5 Market Formulation & Validation

1.6 Model Details

1.7 List of Secondary Sources

1.8 List of Primary Sources

1.9 List of Abbreviations

1.10 Objectives

Chapter 2 Executive Summary

2.1 Market Outlook

2.2 Segment Outlook

2.3 Competitive Insights

Chapter 3 Parenteral Nutrition Market: Variables, Trends & Scope

3.1 Market Lineage Outlook

3.2 Penetration & Growth Prospect Mapping

3.3 User Perspective Analysis

3.4 Regulatory Framework

3.5 Market Variable Analysis

3.6 Parenteral Nutrition Market: Analysis Tools

Chapter 4 Parenteral Nutrition Market: Product Segment Analysis

4.1 Parenteral Nutrition Market: Definition & Scope

4.2 Parenteral Nutrition: Market Share Analysis, 2018 & 2026

4.3 Carbohydrates

4.4 Parenteral Lipid Emulsion

4.5 Single Dose Amino Acid Solution

4.6 Trace Elements

4.7 Vitamins & Minerals

Chapter 5 Parenteral Nutrition Market: Regional Analysis

5.1 Parenteral Nutrition Market: Definition & Scope

5.2 Regional Market Snapshot

5.3 Regional Market Share, 2018

5.4 Parenteral Nutrition Market: Market Share Analysis, 2018 & 2026

5.5 North America

5.6 Europe

5.7 Asia Pacific

5.8 Latin America

5.9 MEA

Chapter 6 Company Profiles

6.1 Company Profiles

  • B. Braun Melsungen AG
  • Fresenius Kabi AG
  • Allergan PLC
  • Grifols S.A.
  • Pfizer Inc. (Hospira)
  • Otsuka Pharmaceutical Factory Inc.
  • Baxter International Inc.
  • Sichuan Kelun Pharmaceutical Co. Ltd.
  • Vifor Pharma
  • Aculife (Nirlife)

Chapter 7 KOL Commentary

7.1 Key Insights

7.2 KOL Views

Chapter 8 Recommendations

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Healthcare Services



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/12/2019 07:34 AM/DISC: 04/12/2019 07:34 AM

Copyright Business Wire 2019.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.